Thromboembolic events in pregnancy: Pharmacological prophylaxis and treatment

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 2917-2931

  Nelson, Scott M ^a   Greer, Ian A ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Arterial thromboembolism; Pregnancy; Therapy; Thrombopropylaxis; Venous thromboembolism

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN; COUMARIN DERIVATIVE; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ORBOFIBAN; PHENPROCOUMON; PROTAMINE SULFATE; SIBRAFIBAN; THROMBIN INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICLOPIDINE; TINZAPARIN; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; ANAPHYLACTIC SHOCK; ANTICOAGULATION; ARTERY THROMBOEMBOLISM; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPRESSION THERAPY; CONGENITAL HEART DISEASE; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; FETOPLACENTAL UNIT; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MACULOPAPULAR RASH; MATERNAL MORBIDITY; MATERNAL MORTALITY; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; POPULATION RESEARCH; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN NECROSIS; TERATOGENICITY; THROMBOEMBOLISM; THROMBOPHILIA; URTICARIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; LIFE STYLE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK ASSESSMENT; RISK FACTORS; STOCKINGS, COMPRESSION; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 37449024717     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.2917     Document Type: Review

References (134)

1. WHITE RH: The Epidemiology of venous thromboembolism. Circulation (2003) 107(90231):I-4-8.
2. WALKER AL, MINISTRY OF HEALTH (Ed.): Report on Confidential Enquiries into Maternal Deaths in England and Wales, 1952-1954. HMSO London (1957).
3. LEWIS GM, DRIFE JO, ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS et al. (Ed.): Why Mothers Die: Confidential Enquiry into Maternal and Child Health: the sixth report of the Confidential Enquiries into Maternal Deaths in the UK. Royal College of Obstetricians and Gynaecologists, London (2004).
4. BERG CJ, ATRASH HK, KOONIN LM, TUCKER M: Pregnancy-related mortality in the United States, 1987-1990. Obstet. Gynecol. (1996) 88(2):161-167.
5. HOGBERG U, INNALA E, SANDSTROM A: Maternal mortality in Sweden, 1980-1988. Obstet. Gynecol. (1994) 84(2):240-244.
6. CHAN W-S, GINSBERG JS: Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy Thromb. Res. (2002) 107(3-4):85-91.
7. NELSON SM, GREER IA: Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. Obstet. Gynecol. Clin. North Am. (2006) 33(3):413-427.
8. PALARETI G, COSMI B, LEGNANI C: Diagnosis of deep vein thrombosis. Semin. Thromb. Hemost. (2006) 32(7):659-672.
9. CHANG J, ELAM-EVANS LD, BERG CJ et al.: Pregnancy-related mortality surveillance - United States, 1991-1999. MMWR Surveill. Summ. (2003) 52(2):1-8.
10. ANDERSON FA Jr, WHEELER HB, GOLDBERG RJ et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch. Intern. Med. (1991) 151(5):933-938.
11. NORDSTROM M, LINDBLAD B, BERGQVIST D, KJELLSTROM T: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. (1992) 232(2):155-160.
12. SAMUELSSON E, HAGG S: Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet. Gynecol. Scand. (2004) 83(7):674-681.
13. MACKLON NS, GREER IA: Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott. Med. J. (1996) 41(3):83-86.
14. LINDQVIST P, DAHLBACK B, MARSAL K: Thrombotic risk during pregnancy: a population study. Obstet. Gynecol. (1999) 94(4):595-599.
15. ANDERSEN BS, STEFFENSEN FH, SORENSEN HT, NIELSEN GL, OLSEN J: The cumulative incidence of venous thromboembolism during pregnancy and puerperium - an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet. Gynecol. Scand. (1998) 77(2):170-173.
16. MCCOLL MD, RAMSAY JE, TAIT RC et al.: Risk factors for pregnancy associated venous thromboembolism. Thromb. Haemost. (1997) 78(4):1183-1188.
17. SIMPSON EL, LAWRENSON RA, NIGHTINGALE AL, FARMER RD: Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG (2001) 108(1):56-60.
18. GHERMAN RB, GOODWIN TM, LEUNG B et al.: Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet. Gynecol. (1999) 94(5 Part 1):730-734.
19. RAY JG, CHAN WS: Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet. Gynecol. Surv. (1999) 54(4):265-271.
20. BLANCO-MOLINA A, TRUJILLO-SANTOS J, CRIADO J et al.: Venous thromboembolism during pregnancy or postpartum: findings from the RIETE registry. Thromb. Haemost. (2007) 97(2):186-190.
21. WALKER ID: Venous and arterial thrombosis during pregnancy epidemiology. Semin. Vasc. Med. (2003) 3(1):25-32.
22. MCGILL HC Jr, MCMAHAN CA, ZIESKE AW et al.: Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation (2000) 102(4):374-379.
23. CLARK P, BRENNAND J, CONKIE JA et al.: Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy Thromb. Haemost. (1998) 79(6):1166-1170.
24. LOCKWOOD CJ: Pregnancy-associated changes in the hemostatic system. Clin. Obstet. Gynecol. (2006) 49(4):836-843.
25. MACKLON NS, GREER IA, BOWMAN AW: An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynaecol. (1997) 104(2):191-197.
26. MACKLON NS, GREER IA: The deep venous system in the puerperium: an ultrasound study. Br. J. Obstet. Gynaecol. (1997) 104(2):198-200.
27. NELSON SM, GREER IA: Artificial reproductive technology and the risk of venous thromboembolic disease. J. Thromb. Haemost. (2006) 4(8):1661-1663.
28. ROBERTSON L, WU O, LANGHORNE P et al.: Thrombophilia in pregnancy: a systematic review. Br. J. Haematol. (2006) 132(2):171-196.
29. GREER IA: Inherited thrombophilia and venous thromboembolism. Best Pract. Res. Clin. Obstet. Gynaecol. (2003) 17(3):413-425.
30. DENTALI F, CROWTHER M: Acquired thrombophilia during pregnancy. Obstet. Gynecol. Clin. North Am. (2006) 33(3):375-388.
31. GRIS JC, LISSALDE-LAVIGNE G, QUERE I, DAUZAT M, MARES P: Prophylaxis and treatment of thrombophilia in pregnancy. Curr. Opin. Hematol. (2006) 13(5):376-381.
32. HERRERA E., AMUSQUIVAR E., LOPEZ-SOLDADO I, ORTEGA H: Maternal lipid metabolism and placental lipid transfer. Horm. Res. (2006) 65(Suppl. 3):59-64.
33. LIAO JK, COCKRILL BA, YURCHAK PM: Acute myocardial infarction after ergonovine administration for uterine bleeding. Am. J. Cardiol. (1991) 68(8):823-824.
34. SONG J-K, PARK S-W, KANG D-H et al.: Safety and clinical impact of ergonovine stress echocardiography for diagnosis of coronary vasospasm. J. Am. Coll. Cardiol. (2000) 35(7):1850-1856.
35. TAYLOR GJ, COHEN B: Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet. Gynecol. (1985) 66(6):821-822.
36. LIVINGSTON JC, MABIE BC, RAMANATHAN J: Crack cocaine, myocardial infarction, and troponin I levels at the time of cesarean delivery. Anesth. Analg. (2000) 91(4):913-915, table of contents.
37. EL MENYAR AA: Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J. Postgrad. Med. (2006) 52(1):51-56.
38. ROSENDAAL FR, SISCOVICK DS, SCHWARTZ SM et al.: A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood (1997) 90(5):1747-1750.
39. LEVINE SR: Hypercoagulable states and stroke: a selective review. CNS Spectr. (2005) 10(7):567-578.
40. MCFAUL PB, DORNAN JC, LAMKI H, BOYLE D: Pregnancy complicated by maternal heart disease. A review of 519 women. Br. J. Obstet. Gynaecol. (1988) 95(9):861-867.
41. WALKER ID: Arterial thromboembolism in pregnancy. Best Pract. Res. Clin. Haematol. (2003) 16(2):297-310.
42. HANANIA G, THOMAS D, MICHEL PL et al.: Pregnancy and prosthetic heart valves: a French cooperative retrospective study of 155 cases. Eur. Heart J. (1994) 15(12):1651-1658.
43. SADLER L, MCCOWAN L., WHITE H et al.: Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG Int. J. Obstet. Gynaecol. (2000) 107(2):245-253.
44. GOHLKE-BARWOLF C, ACAR J, BURCKHARDT D et al.: Guidelines for prevention of thromboembolic events in valvular heart disease. Ad hoc committee of the working group on valvular heart disease, European society of cardiology. J. Heart Valve Dis. (1993) 2(4):398-410.
45. OOSTERHOF T, MEIJBOOM FJ, VLIEGEN HW et al.: Long-term follow-up of homograft function after pulmonary valve replacement in patients with tetralogy of Fallot. Eur. Heart J. (2006) 27(12):1478-1484.
46. DARVALL KA, SAM RC, SILVERMAN SH, BRADBURY AW, ADAM DJ: Obesity and thrombosis. Eur. J. Vasc. Endovasc. Surg. (2007) 33(2):223-233.
47. LARSEN TB, SORENSEN HT, GISLUM M, JOHNSEN SP: Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb. Res. (2007) 120(4):505-509.
48. KAKKOS SK, DASKALOPOULOU SS, DASKALOPOULOS ME, NICOLAIDES AN, GEROULAKOS G: Review on the value of graduated elastic compression stockings after deep vein thrombosis. Thromb. Haemost. (2006) 96(4):441-445.
49. CASELE H, GROBMAN WA: Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet. Gynecol. (2006) 108(3):535-540.
50. DEMPFLE CE: Minor transplacental passage of fondaparinux in vivo. N. Engl. J. Med. (2004) 350(18):1914-1915.
51. WARDA M, GOUDA EM, TOIDA T, CHI L, LINHARDT RJ: Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin. Comp. Biochem. Physiol. C. Toxicol Pharmacol. (2003) 136(4):357-365.
52. BICK RL, FRENKEL EP, WALENGA J, FAREED J, HOPPENSTEADT DA: Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol. Oncol. Clin. North Am. (2005) 19(1):1-51, v.
53. OFOSU FA, SIE P, MODI GJ et al.: The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem. J. (1987) 243(2):579-588.
54. FORESTIER F, DAFFOS F, CAPELLA-PAVLOVSKY M: Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb. Res. (1984) 34(6):557-560.
55. FORESTIER F, DAFFOS F, RAINAUT M, TOULEMONDE F: Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb. Haemost. (1987) 57(2):234.
56. GREER IA, NELSON-PIERCY C: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood (2005) 106(2):401-407.
57. GREINACHER A, ECKHARDT T, MUSSMANN J, MUELLER-ECKHARDT C: Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb. Res. (1993) 71(2):123-126.
58. YOUNG E, PRINS M, LEVINE MN, HIRSH J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb. Haemost. (1992) 67(6):639-643.
59. CHUNILAL SD, YOUNG E., JOHNSTON MA et al.: The APTT response of pregnant plasma to unfractionated heparin. Thromb. Haemost. (2002) 87(1):92-97.
60. LEVINE MN, HIRSH J, GENT M et al.: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch. Intern. Med. (1994) 154(1):49-56.
61. CRUICKSHANK MK, LEVINE MN, HIRSH J, ROBERTS R, SIGUENZA M: A standard heparin nomogram for the management of heparin therapy. Arch. Intern. Med. (1991) 151(2):333-337.
62. RASCHKE RA, REILLY BM, GUIDRY JR, FONTANA JR, SRINIVAS S: The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann. Intern. Med. (1993) 119(9):874-881.
63. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Intern. Med. (1992) 152(8):1589-1595.
64. MOSENKIS A, BERNS JS: Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Semin. Dial. (2004) 17(5):411-415.
65. WARKENTIN TE, LEVINE MN, HIRSH J et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. (1995) 332(20):1330-1335.
66. WARKENTIN TE, GREINACHER A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S311-S337.
67. MURRAY WJ, LINDO VS, KAKKAR VV, MELISSARI E: Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul. Fibrinolysis (1995) 6(2):113-118.
68. CASELE HL, LAIFER SA, WOELKERS DA, VENKATARAMANAN R: Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am. J. Obstet. Gynecol. (1999) 181(5 Part 1):1113-1117.
69. BATES SM, GREER IA, HIRSH J, GINSBERG JS: Use of antithrombotic agents during pregnancy. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S627-S644.
70. SIRAGUSA S, COSMI B, PIOVELLA F, HIRSH J, GINSBERG JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. (1996) 100(3):269-277.
71. VAN DONGEN CJ, VAN DEN BELT AG, PRINS MH, LENSING AW: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst. Rev. (2004) 4:CD001100.
72. VAN DONGEN CJ, MACGILLAVRY MR, PRINS MH: Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. (2005) 3:CD003074.
73. GOULD MK, DEMBITZER AD, DOYLE RI, HASTIE TJ, GARBER AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. (1999) 130(10):800-809.
74. PINI M, AIELLO S, MANOTTI C et al.: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb. Haemost. (1994) 72(2):191-197.
75. VAN DER HEIJDEN JF, HUTTEN BA, BULLER HR, PRINS MH: Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev. (2002) 1:CD002001.
76. HULL RD, PINEO GF, BRANT RF et al.: Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am. J. Med. (2007) 120(1):72-82.
77. BRILL-EDWARDS P, GINSBERG JS, GENT M et al.: Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N. Engl. J. Med. (2000) 343(20):1439-1444.
78. LEE AY, LEVINE MN, BAKER RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. (2003) 349(2):146-153.
79. GREER I, HUNT BJ: Low molecular weight heparin in pregnancy: current issues. Br. J. Haematol. (2005) 128(5):593-601.
80. LEVINE MN, PLANES A, HIRSH J et al.: The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb. Haemost. (1989) 62(3):940-944.
81. NIEUWENHUIS HK, ALBADA J, BANGA JD, SIXMA JJ: Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood (1991) 78(9):2337-2343.
82. LEIZOROVICZ A, BARA L, SAMAMA MM, HAUGH MC: Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis (1993) 23(Suppl. 1):89-98.
83. ALHENC-GELAS M, JESTIN-LE GUERNIC C, VITOUX JF et al.: Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-study group. Thromb. Haemost. (1994) 71(6):698-702.
84. RODIE VA, THOMSON AJ, STEWART FM et al.: Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG (2002) 109(9):1020-1024.
85. BARBOUR LA, OJA JL, SCHULTZ LK: A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am. J. Obstet. Gynecol. (2004) 191(3):1024-1029.
86. ORAN B, LEE-PARRITZ A, ANSELL J: Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb. Haemost. (2004) 92(4):747-751.
87. GINSBERG JS, KOWALCHUK G, HIRSH J, BRILL-EDWARDS P, BURROWS R: Heparin therapy during pregnancy. Risks to the fetus and mother. Arch. Intern. Med. (1989) 149(10):2233-2236.
88. WATERSTONE M, BEWLEY S, WOLFE C: Incidence and predictors of severe obstetric morbidity: case-control study. BMJ (2001) 322(7294):1089-1093; discussion 1093-1094.
89. GRAM J, MERCKER S, BRUHN HD: Does protamine chloride neutralize low molecular weight heparin sufficiently? Thromb. Res. (1988) 52(5):353-359.
90. HIRSH J, RASCHKE R: Heparin and low-molecular-weight heparin. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S188-S203.
91. DOUKETIS JD, GINSBERG JS, BURROWS RF et al.: The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb. Haemost. (1996) 75(2):254-257.
92. BARBOUR LA, KICK SD, STEINER JF et al.: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. (1994) 170(3):862-869.
93. DAHLMAN TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol. (1993) 168(4):1265-1270.
94. BYRD L, JOHNSTONE TA, SHIACH C, HAY CRM: Osteoporotic fracture and low molecular weight heparin. J. Obstet. Gynaecol. (2004) 24(Suppl. 1):S11.
95. BANK I, LIBOUREL EJ, MIDDELDORP S, VAN DER MEER J, BULLER HR: High rate of skin complications due to low-molecular-weight heparins in pregnant women. J. Thromb. Haemost. (2003) 1(4):859-861.
96. VERDONKSCHOT AE, VASMEL WL, MIDDELDORP S, VAN DER SCHOOT JT: Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma. Arch. Gynecol. Obstet. (2005) 271(2):163-165.
97. MYERS B, WESTBY J, STRONG J: Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul. Fibrinolysis (2003) 14(5):485-487.
98. BORCH JE, BINDSLEV-JENSEN C: Delayed-type hypersensitivity to heparins. Allergy (2004) 59(1):118-119.
99. SORENSEN B, JOHANSEN P, NIELSEN GL, SORENSEN JC, INGERSLEV J: Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul. Fibrinolysis (2003) 14(5):469-477.
100. ESKANDARI N, FELDMAN N, GREENSPOON JS: Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet. Gynecol. (2002) 99(5 Part 2):935-937.
101. ANSELL J, HIRSH J, POLLER L et al.: The pharmacology and management of the vitamin K antagonists. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S204-S233.
102. SALEM DN, STEIN PD, AL-AHMAD A et al.: Antithrombotic therapy in valvular heart disease - native and prosthetic. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S457-S482.
103. HORSTKOTTE D, PIPER C, WIEMER M: Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J. Thromb. Thrombolysis (1998) 5:19-24.
104. CHAN WS, ANAND S, GINSBERG JS: Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch. Intern. Med. (2000) 160(2):191-196.
105. COTRUFO M, DE FEO M, DE SANTO LS et al.: Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet. Gynecol. (2002) 99(1):35-40.
106. SCHAEFER C, HANNEMANN D, MEISTER R et al.: Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb. Haemost. (2006) 95(6):949-957.
107. WESSELING J, VAN DRIEL D, HEYMANS HS et al.: Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb. Haemost. (2001) 85(4):609-613.
108. GINSBERG JS, GREER I, HIRSH J: Use of antithrombotic agents during pregnancy. Chest (2001) 119(1 Suppl.):S122-S131.
109. PAULI RM, HALL JG, WILSON KM: Risks of anticoagulation during pregnancy. Am. Heart J. (1980) 100(5):761-762.
110. VILLE Y, JENKINS E., SHEARER MJ et al.: Fetal intraventricular haemorrhage and maternal warfarin. Lancet (1993) 341(8854):1211.
111. KOZER E, NIKFAR S, COSTEI A et al.: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am. J. Obstet. Gynecol. (2002) 187(6):1623-1630.
112. IMPERIALE TF, PETRULIS AS: A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA (1991) 266(2):260-264.
113. KLINZING P, MARKERT UR, LIESAUS K, PEIKER G: Case report: successful pregnancy and delivery after myocardial infarction and essential thrombocythemia treated with dopidrogel. Clin. Exp. Obstet. Gynecol. (2001) 28(4):215-216.
114. UENO M, MASUDA H, NAKAMURA K, SAKATA R: Antiplatelet therapy for a pregnant woman with a mechanical aortic valve: report of a case. Surg. Today (2001) 31(11):1002-1004.
115. SEBASTIAN C, SCHERLAG M, KUGELMASS A, SCHECHTER E: Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin. Cathet. Cardiovasc. Diagn. (1998) 45(3):275-279.
116. CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103(2):201-206.
117. LEONHARDT G, GAUL C, NIETSCH HH, BUERKE M, SCHLEUSSNER E: Thrombolytic therapy in pregnancy. J. Thromb. Thrombolysis (2006) 21(3):271-276.
118. PABINGER I, GRAFENHOFER H, KAIDER A et al.: Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J. Thromb. Haemost. (2005) 3(5):949-954.
119. STEFANO VD, MARTINELLI I, ROSSI E et al.: The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br. J. Haematol. (2006) 135(3):386-391.
120. SBAROUNI E, OAKLEY CM: Outcome of pregnancy in women with valve prostheses. Br. Heart J. (1994) 71(2):196-201.
121. SESHADRI N, GOLDHABER SZ, ELKAYAM U et al.: The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am. Heart J. (2005) 150(1):27-34.
122. BUTCHART EG, GOHLKE-BARWOLF C, ANTUNES MJ et al.: Recommendations for the management of patients after heart valve surgery. Eur. Heart J. (2005) 26(22):2463-2471.
123. GINSBERG JS, CHAN WS, BATES SM, KAATZ S: Anticoagulation of pregnant women with mechanical heart valves. Arch. Intern. Med. (2003) 163(6):694-698.
124. SPANDORFER JM, LYNCH S, WEITZ HH, FERTEL S, MERLI GJ: Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am. J. Cardiol. (1999) 84(4):478-480, A410.
125. MONTALESCOT G, POLLE V, COLLET JP et al.: Low molecular weight heparin after mechanical heart valve replacement. Circulation (2000) 101(10):1083-1086.
126. DOUKETIS JD, JOHNSON JA, TURPIE AG: Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. (2004) 164(12):1319-1326.
127. HULL R, DELMORE T, CARTER C et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. (1982) 306(4):189-194.
128. ANAND SS, BATES S, GINSBERG JS et al.: Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch. Intern. Med. (1999) 159(17):2029-2032.
129. JAMJUTE P, REED N, HINWOOD D: Use of inferior vena cava filters in thromboembolic disease during labor: case report with a literature review. J. Matern. Fetal Neonatal Med. (2006) 19(11):741-744.
130. PILLNY M, SANDMANN W, LUTHER B et al.: Deep venous thrombosis during pregnancy and after delivery: indications for and results of thrombectomy. J. Vasc. Surg. (2003) 37(3):528-532.
131. KUCHER N, KOO S, QUIROZ R et al.: Electronic alerts to prevent venous thromboembolism among hospitalized patients. N. Engl. J. Med. (2005) 352(10):969-977.
132. TAYLOR GM, MCKENZIE CA, MIRES GJ: Use of a computerised maternity information system to improve clinical effectiveness: thromboprophylaxis at caesarean section. Postgrad. Med. J. (2000) 76(896):354-356.
133. DARGAUD Y, RUGERI L, NINET J, NEGRIER C, TRZECIAK MC: Management of pregnant women with increased risk of venous thrombosis. Int. J. Gynecol. Obstet. (2005) 90(3):203-207.
134. GREER IA: Prevention of venous thromboembolism in pregnancy. Best Pract. Res. Clin. Haematol. (2003) 16(2):261-278.